Medi-Caps Limited

Medi-Caps Limited

MEDICAPQ.BO
Medi-Caps LimitedIN flagBombay Stock Exchange
26.36
INR
+0.43
- -
328.71MMarket Cap
Medi-Caps Limited
MEDICAPQ.BO
(Bombay Stock Exchange)

Recent

price

26.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
20.92
20.83
24.07
30.06
28.96
34.46
35.32
39.84
41.53
34.52
46.04
54.78
38.96
21.3
20.44
- -
9.92
Revenue per Share
2.17
1.22
-0.57
-1.04
-1.65
0.69
1.1
0.92
4.32
-4.69
8.92
8.08
1.41
-1.8
-0.46
- -
-2.43
Basic EPS, GAAP
-12.29
0.47
-12.52
-1.41
5.25
1.95
2.65
2.82
4.31
2.71
10.47
3.39
-5.81
5.29
3.82
- -
- -
Free Cash Flow per Basic Share
0.38
0.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
37.25
37.44
43.81
42.38
40.72
41.42
42.51
43.43
47.75
44.03
55.06
60.07
61.48
59.68
10.05
- -
9.98
Book Value per Share
71.5
73.2
72.7
69.11
47.34
48.04
48.88
49.78
54.1
50.37
61.4
70.66
72.52
74.45
75.03
- -
66.82
Tangible Book Value per Share
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
- -
12
Basic Weighted Avg Shares
261
260
300
375
361
430
440
497
518
431
574
683
486
266
254
124
124
Sales/Revenue/Turnover
16.01
9.62
5.64
4.84
-3.82
2.85
-0.19
1.29
5.69
-16.16
18.2
12.08
5.79
-6.48
-13.97
-90.51
-90.5
Operating Margin (%)
9
17
21
21
18
18
18
18
18
17
19
19
18
17
17
18
18
Depreciation Expense
27
15
-7
-13
-21
9
14
11
54
-59
111
101
18
-22
-6
-30
-30
Net Income, GAAP
34.91
61.5
- -
- -
- -
39.32
20.53
14.85
2.12
- -
- -
0.14
62.07
- -
- -
- -
- -
Effective Tax Rate (%)
10.37
5.87
-2.38
-3.46
-5.7
2.01
3.11
2.31
10.4
-13.59
19.38
14.76
3.61
-8.44
-2.25
-24.5
-24.5
Profit Margin (%)
279
213
261
311
208
222
263
281
329
298
434
535
538
548
503
443
443
Working Capital
- -
3
63
89
8
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
892
913
907
862
814
823
891
902
956
910
1,047
1,163
1,186
1,210
1,213
1,116
1,116
Total Equity
3.71
1.06
- -
- -
- -
0.9
-0.08
0.6
3.08
- -
- -
7.45
0.9
- -
- -
- -
- -
Return on Invested Capital (%)
5.89
4.41
- -
- -
- -
1.7
2.63
2.15
9.48
- -
- -
14.06
2.32
- -
- -
- -
- -
Return on Capital (%)
5.94
3.28
-1.41
-2.41
-3.98
1.69
2.61
2.14
9.48
-10.23
18.01
14.04
2.32
-2.97
-1.31
-24.36
-24.36
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
- -
12
Market Capitalization
463
390
290

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
476
- -
470
Cash, Cash Equivalents & STI
250
- -
239
Accounts Receivable, Net
59
- -
69
Inventories
47
- -
29
Total Current Liabilities
36
- -
27
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.31%
1.46%
-7.97%
Free Cash Flow
-47.89%
-164.79%
-265.91%
Net Income, GAAP
-4.93%
7.56%
431.96%
Sales/Revenue/Turnover
-7.48%
-22.17%
-51.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
60
69
74
266
2025
61
83
40
69
254
2026
27
20
43
34
124

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.89
0.09
-0.13
- -
-1.8
2025
-0.45
0.25
-1.64
1.38
-0.46
2026
-2.8
-1.46
-0.61
2.44
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Medi-Caps Limited operates as a flagship manufacturing company specializing in the production of empty hard gelatin capsules primarily used in the pharmaceutical industry. The company offers a diverse range of capsule products including regular empty hard gelatin capsules; specialized capsules such as flavored capsules, Halal gelatin capsules, preservative-free capsules, SLS-free capsules, and sweet capsules; liquid fill capsules designed for semi-liquid, paste, and liquid formulations; and metallic-colored Pearlz capsules. Its manufacturing facilities incorporate international-standard automatic machines and utilize high-quality gelatin sourced domestically. Medi-Caps serves a broad customer base domestically and internationally, exporting approximately 40% of its production to regions including the Far East, Middle East, South East Asia, and Africa, with ongoing efforts to expand into the European market, particularly with TSE-free gelatin capsules that meet stringent European regulatory requirements. The company maintains a robust client portfolio with multinational pharmaceutical companies. Medi-Caps was incorporated in 1986 and is headquartered in Pithampur, Madhya Pradesh, India. It is part of the Medi-Caps Group and remains listed on the Bombay Stock Exchange (BSE) under the ticker MEDICAPQ. Recent developments within the last two years indicate significant operational challenges including declining revenue and escalating losses primarily driven by a contraction in sales, with Q2 FY26 revenues reported at notably low levels compared to previous years. The company is actively addressing these challenges through cost restructuring and exploring new pharmaceutical customer contracts aimed at stabilizing and eventually restoring profitability. While no major acquisitions or partnerships have been publicly highlighted recently, strategic focus appears directed at operational resilience and market share expansion through product innovation and geographic market penetration. Medi-Caps operates mainly in the pharmaceutical excipients segment, supplying empty gelatin capsules to pharmaceutical manufacturers worldwide. Its operational footprint extends through domestic markets in India and international markets with expanding presence in Europe. The company’s specialization in multiple capsule types, adherence to regulatory standards, and manufacturing modernization efforts position it as a specialized supplier in this niche industry sector. Its extensive quality control infrastructure supports compliance with global health and safety standards, reinforcing its reputation amid competitive dynamics in pharmaceutical capsule manufacturing.